login
  Password reminder
NeuroNews
Contact the editor Visit NeuroNews Twitter feed Visit NeuroNews Facebook page
 

Encouraging early clinical results with Woven Endobridge cerebral aneurysm device


Friday, 16 Dec 2011 12:53

Flow diversion is a new approach for the endovascular treatment of intracranial aneurysms. The Woven Endobridge (WEB II, from Sequent Medical) cerebral aneurysm embolization device is an intrasaccular, oblate, braided-wire designed to provide flow disruption at the aneurysm neck-parent artery interface. A new study suggests that early data from the first two patients treated with the device is hopeful. 


A study published in August 2011 in the journal Neuroradiology suggests that the intrasaccular deployment of self-expanding, compliant, cylindrical, high-density, braided metallic mesh constructs could represent a reasonable approach as an endovascular treatment of cerebral aneurysms.


Investigators Joachim Klisch, Department of Diagnostic and Interventional Radiology and Neuroradiology, Helios General Hospital, Erfurt, Germany, and colleagues set out to evaluate the acute and short-term performance of the WEB II device regarding the immediacy, degree, and durability of aneurysm occlusion in two patients.


Klisch et al implanted the WEB II device in one patient with an unruptured middle cerebral artery trifurcation aneurysm and in another with an unruptured basilar tip aneurysm. They then graded the degree of intra-aneurysmal flow disruption based on serial digital subtraction aneurysm angiography performed over 30 min immediately following device implantation and at eight weeks. The team also performed immediate and eight-week post-treatment CT and 3-T MRI studies.


The authors wrote in the journal, “Delivery and deployment of the WEB II device was technically straightforward and achieved without complications.” Further, they noted that neither of the two devices required retrieval or repositioning after full deployment and there were no periprocedural thrombembolic or haemorrhagic complications. “In both cases, complete aneurysm occlusion was observed within minutes of device deployment. Short-term angiographic follow-up confirmed stable complete occlusion at eight weeks,” they noted. The authors also recommended in the paper that further clinical studies and long-term follow-up with the device should be pursued.


Tom Wilder, president and CEO of Sequent Medical told NeuroNews, “Sequent Medical is conducting a controlled release of the WEB Aneurysm Embolization system, which bears the CE mark, at a number of selected centres in Europe in order to gain further clinical experience. The company intends to initiate a number of clinical studies during 2012.”

 




Add New Comment

Most popular


Better outcomes observed in MR CLEAN non-general anaesthesia subgroup in post-hoc analysis
Thursday, 02 Apr 2015
In a post-hoc analysis of the use of general anaesthesia in the MR CLEAN trial (Multicenter randomized clinical trial of endovascular treatment for acute ischemic stroke in the Netherlands) ... Better outcomes observed in MR CLEAN non-general anaesthesia subgroup in post-hoc analysis

Cover device proves more effective than guide catheter in stroke model
Wednesday, 18 Mar 2015
In an in vitro stroke model comparison, the use of the Cover accessory device (Lazarus Effect) in conjunction with a stent retriever resulted in higher successful recanalisation rates, no embolic ... Cover device proves more effective than guide catheter in stroke model

Evidence builds for endovascular treatment of acute ischaemic stroke
Friday, 17 Apr 2015
With the publication of two more stroke trials, the evidence in favour of endovascular treatment in patients with acute ischaemic stroke has reached new heights. Data from SWIFT PRIME and REVASCAT ... Evidence builds for endovascular treatment of acute ischaemic stroke

Features


New day in acute ischaemic stroke therapy
Friday, 17 Apr 2015
The newest generation of trials for acute ischaemic stroke, including MR CLEAN, ESCAPE, EXTEND IA and SWIFT PRIME, appear to have ushered in a new era in stroke therapy. Now, Joseph Broderick (... New day in acute ischaemic stroke therapy

Flow diverter technology for intracranial aneurysms
Tuesday, 31 Mar 2015
Gabor Toth writes for NeuroNews about the flow diverters that are currently available and the ongoing clinical trials that could have the potential to extend the indications of flow diverter therapy ... Flow diverter technology for intracranial aneurysms

Profiles


Joseph Broderick
Wednesday, 07 Jan 2015
Joseph Broderick speaks to NeuroNews about the future of neurology and his research, in particular, ... Joseph Broderick

Vladimír Beneš Jr
Tuesday, 30 Sep 2014
Vladimír Beneš Jr is professor and chair at the First Medical School, Charles University, P... Vladimír Beneš Jr

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions